Adam Feuerstein

Can any of the new obesity medications in development stand out from the pack? Which company just broke records with its IPO? And will the Food and Drug

The FDA has reversed its opposition to a closely watched experimental treatment for Huntington’s disease, clearing a path for its maker.

A wide gap exists between what Patrick Soon-Shiong says his cancer drugs can achieve and what they actually do, STAT's Adam Feuerstein writes.

This week on "The Readout LOUD" podcast: new hope in treating Huntington's disease and a report card on RFK Jr.'s promises. Listen now.

Here is STAT's biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter:

The Food and Drug Administration on Tuesday approved a personalized T-cell therapy from Orca Bio, a private biotech company, that reduces the risk of a debilitating immune reaction in patients with blood cancers undergoing stem cell transplants.

Plus: What to expect at the FDA's Capricor advisory panel meeting This story first appeared in Adam's Biotech Scorecard, a subscriber-only newsletter.

The Food and Drug Administration on Tuesday approved a new medicine from the biotech company Vera Therapeutics for patients with a type of chronic autoimmune kidney disease.

Why the extra-long delay on a review of Northwest Biotherapeutics' brain cancer treatment?

Why does getting family health insurance through a job cost as much as buying a new car? How did a whistleblower take on an insurance contractor?